One of the advantages of my strategy is that I always look for growth stocks with doubling potential before the broad market discovers them, even if this naturally entails a higher risk. I recently came across $ONWD (-1,49 %) recently. As it is a medtech company, it might also be interesting for the dear@Tenbagger2024 .
The neurotech company has three technology platforms with which it aims to give as many people as possible with restricted mobility a significantly better quality of life. The company's ARC-EX system is already approved in the USA (now also for home use) and Europe. Onward Medical is therefore entering the commercial phase. In the third quarter alone, the company sold 40 of these systems, which can now give people with spinal cord injuries a better quality of life.
While Onward Medical is making clear progress on the commercial side, the broad development pipeline is also being driven forward. Among other things, the company also wants to develop neurotech solutions for blood pressure management or Parkinson's disease. Apparently, the newcomer to the stock market Ottobock also finds the Onward Medical story appealing. As part of a capital measure in October, the prosthesis manufacturer once again invested money in the European neurotech hopeful. "The company's developments fit perfectly into our future strategy for neuroorthetics. We are therefore pleased to strengthen our role as the largest shareholder as well as our strategic partnership through our additional investment," says Ottobock CEO Oliver Jakobi.
After AI and quantum computing, neurotech could become the next megatrend on the stock market. In my opinion, Onward Medical has everything it takes to be valued significantly higher. On top of that, there is a shot of takeover fantasy.
I therefore think I will add a few shares to my portfolio.
